1. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008; 8(4): 253-267. doi: 10.1038/nrc2347
2. Bencivenga D, Caldarelli I, Stampone E, et al. p27(Kip1) and human cancers: A reappraisal of a still enigmatic protein. Cancer Lett. 2017; 403: 354-365. doi: 10.1016/j.canlet.2017.06.031
3. Wander SA, Zhao D, Slingerland JM. p27: A barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res. 2011; 17(1): 12-18. doi: 10.1158/1078- 0432.CCR-10-0752
4. Jia W, He M-X, McLeod IX, Guo J, Ji D, He Y-W. Autophagy regulates T lymphocyte proliferation through selective degradation of the cell-cycle inhibitor CDKN1B/p27Kip1. Autophagy. 2015; 11(12): 2335-2345. doi: 10.1080/15548627.2015.1110666
5. Sun X, Momen A, Wu J, et al. p27 protein protects metabolically stressed cardiomyocytes from apoptosis by promoting autophagy. J Biol Chem. 2014; 289(24):16924-16935. doi: 10.1074/jbc.M113.542795
6. Levkau B, Koyama H, Raines EW, et al. Cleavage of p21Cip1/ Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell. 1998; 1(4): 553-563. doi: 10.1016/s1097-2765(00)80055-6
7. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994; 78(1): 59- 66. doi: 10.1016/0092-8674(94)90572-x
8. Occhi G, Regazzo D, Trivellin G, et al. A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet. 2013; 9(3): e1003350. doi: 10.1371/journal.pgen.1003350
9. Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2011; 96(4): E701-E706. doi: 10.1210/jc.2010-1338
10. Dietrich S, Hüllein J, Lee SC, et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015; 126(8): 1005-1008. doi: 10.1182/blood-2015-04-643361
11. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403): 400-404. doi: 10.1038/nature11017
12. Maxwell JE, Sherman SK, Li G, et al. Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors. Cancer Genet. 2015; pii: S2210-S7762(15): 00184-00192. doi: 10.1016/j.cancergen.2015.08.003
13. Crona J, Gustavsson T, Norlén O, et al. Somatic mutations and genetic heterogeneity at the CDKN1B locus in small intestinal neuroendocrine tumors. Ann Surg Oncol. 2015; 22 Suppl 3: S1428- S1435. doi: 10.1245/s10434-014-4351-9
14. Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013; 45(12): 1483-1486. doi: 10.1038/ng.2821
15. Viglietto G, Motti ML, Fusco A. Understanding p27(kip1) deregulation in cancer: Down-regulation or mislocalization. Cell Cycle. 2002; 1(6): 394-400. doi: 10.4161/cc.1.6.263
16. Masciullo V, Sgambato A, Pacilio C, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 1999; 59(15): 3790-3794. https://pubmed.ncbi.nlm.nih.gov/10446997/
17. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997; 3(2): 231-234. doi: 10.1038/nm0297-231
18. McCampbell AS, Mittelstadt ML, Dere R, et al. Loss of p27 associated with risk for endometrial carcinoma arising in the setting of obesity. Curr Mol Med. 2016; 16(3): 252-265. doi: 10.2174/1566 524016666160225153307
19. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barrett’s associated adenocarcinoma. Cancer Res. 1998; 58(8): 1730-1735. https://pubmed.ncbi.nlm.nih.gov/9563491/
20. Sgambato A, Ratto C, Faraglia B, et al. Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog. 1999; 26(3): 172-179. doi: 10.1002/(SICI)1098-2744(199911)26:33.0.CO;2-8
21. Shehata MA, Nosseir HR, Nagy HM, Farouk G. Cyclin dependent kinase inhibitor p27(kip1) expression and subcellular localization in relation to cell proliferation in hepatocellualr carcinoma. Egypt J Immunol. 2006; 13(1): 115-130. https://pubmed.ncbi.nlm.nih.gov/17974156/
22. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002; 8(10): 1136-1144. doi: 10.1038/nm762
23. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997; 3(2): 227-230. https://pubmed.ncbi.nlm.nih.gov/9018244/
24. McCampbell AS, Walker CL, Broaddus RR, Cook JD, Davies PJ. Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the rat. Lab Invest. 2008; 88(6): 615-626. doi: 10.1038/labinvest.2008.29
25. Oshita F, Kameda Y, Nishio K, et al. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol Rep. 2000; 7(3): 491-495. doi: 10.3892/or.7.3.491
26. Korkolopoulou P1, Vassilopoulos I, Konstantinidou AE, et al. The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol. 2002; 85(3): 404-414. doi: 10.1006/gyno.2002.6627
27. Han S, Park K, Kim HY, et al. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res Treat. 1999; 55(2): 161-167. doi: 10.1023/a:1006258222233
28. Moreno-Galindo C, Hermsen M, García-Pedrero JM, et al. p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol. 2014; 50(2): 128- 134. doi: 10.1016/j.oraloncology.2013.10.018
29. Cook JD, Davis BJ, Cai SL, Barrett JC, Conti CJ, Walker CL. Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. Proc Natl Acad Sci U S A. 2005; 102(24): 8644-8649. doi: 10.1073/pnas.0503218102
30. Mas A, Stone L, O’Connor PM. Developmental exposure to endocrine disruptors expands murine myometrial stem cell compartment as a prerequisite to leiomyoma tumorigenesis. stem cells. 2017; 35(3): 666-678. doi: 10.1002/stem.2519